Skip to main content
TipRanks
Go Ultimate75% OFF
VarmX logo

VarmX: Valuation, Funding & Investors

VarmX is a biotechnology company based in Leiden, the Netherlands, specializing in the development of innovative therapies for patients on direct oral anticoagulants targeting activated Factor Xa and those with inherited coagulation disorders. The company's lead product, VMX-C001, is designed to bypass the anticoagulation effects of Factor Xa inhibitors, rapidly restoring coagulation in patients experiencing severe bleeding or requiring urgent surgery. VarmX's efforts address a significant unmet need in emergency care, with no fully approved therapeutic agents currently available in the E.U. or the U.S. for such conditions.

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$117M
Total Funding Rounds
1
Latest Funding Amount
$117M
Latest Funding Round
Series B

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Sep 16, 2025Series B$117.00M―

Investors

Investor NameFunding Round
EQT Life SciencesSeries B
InnovationQuarterSeries B
Ysios CapitalSeries B
EICSeries B
Sound BioventuresSeries B
InkefSeries B
Lundbeckfonden BioCapitalSeries B
BioGeneration VenturesSeries B

Similar Companies

A snapshot of private companies similar to VarmX, helping you discover and navigate related company profiles.

Related News and Analysis